Abbvie’s bid for Allergan shows that the Botox franchise is impenetrable. The market agrees.
Chiasma hopes to be able to file its oral acromegaly therapy by year-end, and Novartis wants to shore up its MS franchise.
Bristol-Myers Squibb’s $74bn bid for Celgene led to a huge quarter, but a drop in the deal count could give pause to those hoping for a bumper year.
A run of acquisitions of recent biotech IPOs is great news for investors who backed these companies, but the reality is that a large majority of fledgling drug stocks are…
In placing a $1bn bet on the rare disease player Clementia, Ipsen is banking on a lenient US regulator.
Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?
The keenly awaited unveiling of full data from Pfizer/Merck KGaA’s Javelin Renal 101 trial has not disappointed.
The US biotech claims an unexpected victory, scoring a $2.1bn takeover by Novartis on the strength of an asset it had bought for just $12m.
Big pharma is using machine learning to improve the drug development process – but can the tech live up to the hype?